Trials / Completed
CompletedNCT05034952
A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-dose Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 303 (actual)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating acute pain after an abdominoplasty.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VX-548 | Tablets for oral administration. |
| DRUG | HB/APAP | Capsules for oral administration. |
| DRUG | Placebo (matched to VX-548) | Placebo matched to VX-548 for oral administration. |
| DRUG | Placebo (matched to HB/APAP) | Placebo matched to HB/APAP for oral administration. |
Timeline
- Start date
- 2021-08-30
- Primary completion
- 2021-12-05
- Completion
- 2021-12-21
- First posted
- 2021-09-05
- Last updated
- 2024-12-27
- Results posted
- 2024-12-27
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05034952. Inclusion in this directory is not an endorsement.